Mirum Pharmaceuticals Inc MIRM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Trading Information
- Previous Close Price
- $94.61
- Day Range
- $92.24–94.80
- 52-Week Range
- $63.31–129.80
- Bid/Ask
- $94.29 / $94.66
- Shares Outstanding
- 65.28M
- Market Cap
- $6.14B
- Volume/Avg
- 64,553 / 689,747
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 470
- Website
- https://www.mirumpharma.com
Valuation
Metric | MIRM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 8.44 |
Price/Cash Flow | — |
Price/Earnings
MIRM
Financial Strength
Metric | MIRM |
|---|---|
Quick Ratio | 1.87 |
Current Ratio | 2.07 |
Interest Coverage | −79.06 |
Quick Ratio
MIRM
Profitability
Metric | MIRM |
|---|---|
Return on Assets (Normalized) | −27.73% |
Return on Equity (Normalized) | −162.23% |
Return on Invested Capital (Normalized) | −39.58% |
Return on Assets
MIRM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|^J%V$d | LOCK|nV@M | $139B | |||
| Moderna Inc MRNA | LOCK|&P!?#&Z | LOCK|$!t | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|STY^r> | LOCK|!<&@& | $99B | |||
| argenx SE ADR ARGX | LOCK|%!NK&>J | LOCK|^dV | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|TyTF$H | LOCK|q? | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|cZF$Xp<T | LOCK|?k>&s | $31B | |||
| Incyte Corp INCY | LOCK|Z^%^n? | LOCK|W<W | $25B | |||
| BioNTech SE ADR BNTX | LOCK|mQZX>Yy | LOCK|%& | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#fvf!yH | LOCK|bS>J | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|smwQg& | LOCK|TH | $16B |
United States